Imagion Biosystems appoints Dr. Isaac Bright as CEO to drive next phase of growth
Melbourne, Australia: Imagion Biosystems (ASX: IBX), a leading healthcare company focused on early cancer detection, is thrilled to announce the appointment of Dr. Isaac Bright as its new Chief Executive Officer, effective June 20, 2023.
Dr. Bright brings over two decades of experience as a results-focused business leader, health industry executive, and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. His extensive expertise makes him an ideal fit to lead Imagion in its next phase of growth, building upon the success the company has achieved thus far with its innovative MagSense nanoparticle technology.
Chairman Bob Proulx expressed his enthusiasm for Dr. Bright’s appointment, stating, “We are very pleased to have attracted someone of Dr. Bright’s caliber to Imagion. With his track record in strategic partnering, financing, and mergers and acquisitions, we believe he is well-suited to support our vision and drive the next chapter in Imagion’s growth. I look forward to working with Dr. Bright to create value for our shareholders, and we are excited to welcome him to our team.”
Dr. Bright also shared his excitement about joining Imagion Biosystems, stating, “Imagion Biosystems is a pioneer in clinical molecular imaging and nanoparticle innovation, and I look forward to working with the Board and my new colleagues to advance our clinical pipeline and capabilities. Leading the Imagion team is a great honor, and I am committed to driving the company’s continued success in providing new solutions for cancer patients and their care teams.”
The appointment of Dr. Bright follows the recent announcement on April 28, 2023, regarding the retirement of Bob Proulx from the role of CEO. Mr. Proulx will continue serving as Chairman of the Board. In preparation for Mr. Proulx’s retirement, Imagion Biosystems engaged an executive search firm earlier this year to identify experienced candidates with backgrounds in biopharmaceuticals and imaging. The search focused on candidates to be based at the company’s U.S. headquarters in San Diego.
The Remuneration and Nomination Committee of the Board, in collaboration with the search firm, meticulously screened over 60 candidates during the recruitment process. Ms. Dianne Angus, Chair of the Remuneration and Nomination Committee, expressed satisfaction with the quality of candidates and the selection of Dr. Bright. She stated, “We were determined to attract an executive with both scientific and business competence to drive product development to commercialization. With our manufacturing and nanoparticle technical innovation teams based in San Diego and numerous prospective strategic partners in the U.S., it was crucial to have hands-on leadership in San Diego. We are delighted to have employed someone as well-credentialed as Dr. Bright and eagerly anticipate his contributions to Imagion.”
Dr. Isaac Bright’s appointment as CEO marks a significant milestone for Imagion Biosystems as it continues to advance its groundbreaking technologies and strengthen its position in the field of cancer diagnostics.
About The Author
